Zhang Fangliang

All filings by Zhang Fangliang on record concern Genscript Biotech Corporation. We count 105 filings; the first trade dates from 13 July 2017 and the latest from 22 June 2026.

Both buying and selling appear: 6 purchases worth €216.2M, against 49 sales worth €262.1M. The totals exclude 6 filings filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. 2026 to date brings 1 purchase and no sales.

The median purchase comes to €409k. 5 out of 6 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. For 4 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 0% of cases, with a median move of -2.7%. These figures describe past trades and do not predict future prices.

On 26 June 2026 came the latest disclosure, a transaction in Genscript Biotech Corporation. The last purchase on record was published on 10 June 2026, which is 136 days ago. Filings reach the HKEX feed a median of 4 days after the trade. That lag is the time during which only the insider knows about the trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from HKEX. Past trades are no guide to future returns.